ImmunityBio says Anktiva plus BCG showed durable survival and bladder preservation at 36 months in BCG-unresponsive bladder ...
The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the ...
Merck, Pfizer and Astellas, which in August reported similar results from a Phase 3 study of the combination in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based ...
16hon MSN
Pfizer, Astellas post late-stage trial win for Padcev in bladder cancer with Merck’s Keytruda
Pfizer (PFE) and Astellas Pharma (ALPMY) announced on Wednesday that their antibody drug conjugate Padcev, with Merck’s (MRK) ...
Merck says Keytruda plus Padcev improved survival and response rates versus chemotherapy in a Phase 3 muscle-invasive bladder ...
A groundbreaking study introduces new noninvasive screening tools that have the potential to greatly enhance patient comfort ...
Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as a perioperative therapy for ...
“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of ...
Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced that European Urology Oncology published results of a clinical study demonstrating ...
Researchers have found in a Finnish population-based cohort study that diabetes and poor glycemic status were associated with ...
Scientists uncovered how childhood BK virus infections may set off cancer-causing mutations decades later: by activating a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback